ImmuneBiotech AB - a microbiome company developing and marketing scientifically proven super-consortia of probiotic strains.
The first product, GutMagnific™ is patent pending and scientifically designed to address the underlying causes of IBS. The product will be launched as probiotic food supplement in 2019. It is differentiated by effectively addressing multiple areas: microbial imbalance (dysbiosis), intestinal permeability and inflammation. GutMagnific™ has potential in many applications, such as diarrhea, antibiotic induced diarrhea, Clostridium difficile infection (CDI) and Chronic Fatigue Syndrome (ME/CFS).
ImmuneBiotech is building a pipeline within its concept of Companion Probiotics®, here selected probiotic combinations are designed for use together with existing drugs.